Roeland GW Verhaak, PhD, assistant professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the alteration of the p53 pathway and ancestral progenitors to determine if they were associated with tumor recurrence in glioblastoma.
Roeland GW Verhaak, PhD, assistant professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the alteration of the p53 pathway and ancestral progenitors to determine if they were associated with tumor recurrence in glioblastoma.
Clinical Pearls:
<<<
New APL Treatment Shows Promise: Higher Survival Rates, Less Toxicity
July 6th 2024ATO/ATRA plus idarubicin showed superior 2-year EFS (88% vs 70%) and 5-year EFS (87% vs 55%) compared to ATRA/chemotherapy. The trial indicated lower hematologic toxicity with ATO/ATRA, including reduced rates of thrombocytopenia and neutropenia.
Read More